6j12 - Revision history

OCA at 07:35, 1 May 2024

OCA — Wed, 01 May 2024 07:35:38 GMT

←Older revision		Revision as of 07:35, 1 May 2024
Line 1:		Line 1:

	==Three-dimensional Solution NMR Structure of KYE28-PEG48 in Microgel==		==Three-dimensional Solution NMR Structure of KYE28-PEG48 in Microgel==
-	<StructureSection load='6j12' size='340' side='right' caption='[[6j12~~]], [[NMR_Ensembles_of_Models \| 20 NMR models~~]]' scene=''>	+	<StructureSection load='6j12' size='340' side='right'caption='[[6j12]]' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6j12]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6J12 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6J12 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6j12]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6J12 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6J12 FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6j12 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6j12 OCA], [~~http~~://pdbe.org/6j12 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6j12 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6j12 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6j12 ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6j12 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6j12 OCA], [https://pdbe.org/6j12 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6j12 RCSB], [https://www.ebi.ac.uk/pdbsum/6j12 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6j12 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/HEP2_HUMAN HEP2_HUMAN]] Defects in SERPIND1 are the cause of thrombophilia due to heparin cofactor 2 deficiency (THPH10) [MIM:[~~http~~://omim.org/entry/612356 612356]]. A hemostatic disorder characterized by a tendency to recurrent thrombosis.<ref>PMID:2647747</ref> <ref>PMID:10391209</ref> <ref>PMID:11204559</ref> <ref>PMID:15337701</ref>	+	[https://www.uniprot.org/uniprot/HEP2_HUMAN HEP2_HUMAN] Defects in SERPIND1 are the cause of thrombophilia due to heparin cofactor 2 deficiency (THPH10) [MIM:[https://omim.org/entry/612356 612356]. A hemostatic disorder characterized by a tendency to recurrent thrombosis.<ref>PMID:2647747</ref> <ref>PMID:10391209</ref> <ref>PMID:11204559</ref> <ref>PMID:15337701</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/HEP2_HUMAN HEP2_HUMAN]] Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.<ref>PMID:1939083</ref> Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.<ref>PMID:1939083</ref>	+	[https://www.uniprot.org/uniprot/HEP2_HUMAN HEP2_HUMAN] Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.<ref>PMID:1939083</ref> Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.<ref>PMID:1939083</ref>
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Bhunia, A~~]]	+	[[Category: Homo sapiens]]
-	[[Category: ~~Ilyas, H~~]]	+	[[Category: Large Structures]]
-	[[Category: ~~Antimicrobial peptide~~]]	+	[[Category: Bhunia A]]
-	[[Category: ~~Antimicrobial protein]]~~	+	[[Category: Ilyas H]]
-	~~[[Category: Drug delivery]]~~	+
-	~~[[Category: Microgel]]~~	+
-	~~[[Category: Pegylation~~]]	+

OCA at 12:13, 16 January 2019

OCA — Wed, 16 Jan 2019 12:13:10 GMT

←Older revision		Revision as of 12:13, 16 January 2019
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6j12 is ~~ON HOLD~~	+	==Three-dimensional Solution NMR Structure of KYE28-PEG48 in Microgel==
-		+	<StructureSection load='6j12' size='340' side='right' caption='[[6j12]], [[NMR_Ensembles_of_Models \| 20 NMR models]]' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[6j12]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6J12 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6J12 FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6j12 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6j12 OCA], [http://pdbe.org/6j12 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6j12 RCSB], [http://www.ebi.ac.uk/pdbsum/6j12 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6j12 ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased Structures~~]]	+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/HEP2_HUMAN HEP2_HUMAN]] Defects in SERPIND1 are the cause of thrombophilia due to heparin cofactor 2 deficiency (THPH10) [MIM:[http://omim.org/entry/612356 612356]]. A hemostatic disorder characterized by a tendency to recurrent thrombosis.<ref>PMID:2647747</ref> <ref>PMID:10391209</ref> <ref>PMID:11204559</ref> <ref>PMID:15337701</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/HEP2_HUMAN HEP2_HUMAN]] Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.<ref>PMID:1939083</ref> Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.<ref>PMID:1939083</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Bhunia, A]]
		+	[[Category: Ilyas, H]]
		+	[[Category: Antimicrobial peptide]]
		+	[[Category: Antimicrobial protein]]
		+	[[Category: Drug delivery]]
		+	[[Category: Microgel]]
		+	[[Category: Pegylation]]

OCA: Protected "6j12" [edit=sysop:move=sysop]

OCA — Wed, 02 Jan 2019 04:51:50 GMT

Protected "6j12" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:51, 2 January 2019

OCA: New page: '''Unreleased structure''' The entry 6j12 is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 02 Jan 2019 04:51:49 GMT

New page: '''Unreleased structure''' The entry 6j12 is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6j12 is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]